Literature DB >> 22586058

Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Xuewei Zhuang1, Xiaoning Zhang, Xiyan Xia, Cuijuan Zhang, Xiaohong Liang, Lifen Gao, Xin Zhang, Chunhong Ma.   

Abstract

T-cell immunoglobulin- and mucin domain-3-containing molecule 3 (TIM-3) is a membrane protein expressed in various kinds of immune cells and plays a pivotal role in immune regulation. Recently, TIM-3 was reported to be expressed aberrantly in melanoma cells, contributing to the low adhesion ability of tumor cells and promoting the survival of melanoma cells. We investigated TIM-3 expression in non-small cell lung cancers (NSCLCs), and further analyzed whether the aberrant expression of TIM-3 is related to the prognosis for patients with lung cancer. Tumor tissue samples from 30 patients with NSCLC were involved. Results of immunohistochemical analysis showed that TIM-3 stained positive on tumor cells in 86.7% (26/30) patients with primary NSCLC. The TIM-3 expression in NSCLC tumor cells was correlated with histologic type and pathologic T classification of the disease (P < .05). More importantly, patients with TIM-3-positive tumor cells had a significantly shorter survival time than those with TIM-3-negative tumors. Multivariate analysis demonstrated the significant role of TIM-3 expression in tumor cells as an independent prognostic factor for patients with NSCLC (relative risk, 4.481; 95% confidence interval, 1.790-11.22; P = .0005). Our results suggest that the ectopic expression of TIM-3 in tumor cells may be a potential, independent prognostic factor for patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22586058     DOI: 10.1309/AJCP9Q6OVLVSHTMY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  44 in total

1.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

2.  Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3.

Authors:  Vida Homayouni; Hossein Khanahmad; Mazdak Ganjalikhani-Hakemi; Mahdi Behdani; Pouria Ghasemi; Abbas Rezaei
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

3.  Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma.

Authors:  Jingwei Li; Dayan Cao; Guoning Guo; Yuzhang Wu; Yongwen Chen
Journal:  J Mol Histol       Date:  2012-12-21       Impact factor: 2.611

4.  Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.

Authors:  Gui Cheng; Min Li; Jun Wu; Mei Ji; Cheng Fang; Hongbing Shi; Danxia Zhu; Lujun Chen; Jiemin Zhao; Liangrong Shi; Bin Xu; Xiao Zheng; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Expression of Tim-3 in breast cancer tissue promotes tumor progression.

Authors:  Shiqing Cheng; Fuyan Han; Yanqiu Xu; Teng Qu; Ying Ju
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

6.  Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis.

Authors:  Hualin Zhang; Yang Song; Huimin Yang; Zhiyan Liu; Lifen Gao; Xiaohong Liang; Chunhong Ma
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

Review 7.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

8.  TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma.

Authors:  Hasita Horlad; Koji Ohnishi; Chaoya Ma; Yukio Fujiwara; Daisuke Niino; Koichi Ohshima; Masahisa Jinushi; Masao Matsuoka; Motohiro Takeya; Yoshihiro Komohara
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

9.  T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer.

Authors:  Jianwen Bai; Xiaoyan Li; Danian Tong; Weiwei Shi; Haihan Song; Qinchuan Li
Journal:  Tumour Biol       Date:  2013-01-29

10.  Up-regulation of Tim-3 is associated with poor prognosis of patients with colon cancer.

Authors:  Encheng Zhou; Qing Huang; Ji Wang; Chengfeng Fang; Leilei Yang; Min Zhu; Jianhui Chen; Lihua Chen; Milian Dong
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.